UPDATE: Intellia Therapeutics (NTLA) PT Lowered to $83 at Morgan Stanley (correction)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intellia Therapeutics (NTLA) PT Lowered to $53 at Wedbush
November 3, 2022 11:36 AM EDTWedbush analyst David Nierengarten lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $53.00 (from $58.00) while maintaining a Neutral rating.... More
Intellia Therapeutics (NTLA) Misses Q3 EPS by 20c
November 3, 2022 7:36 AM EDTIntellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($1.49), $0.20 worse than the analyst estimate of ($1.29). Revenue for the quarter came in at $13.27 million versus the consensus estimate of $11.43 million.
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
... More